|
Select Publications
Aapro MS. Long-term implications of bone loss in breast cancer. Breast 2004;13(Suppl 1):29-37. Abstract
Boccardo F. Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer. Clin Breast Cancer 2004;5(Suppl 1):13-7. Abstract
Coombes RC et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081-92. Abstract
Dixon JM et al. Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status. Eur J Cancer 2004;40(18):2742- 7. Abstract
Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer. Cochrane Database Syst Rev 2001;(1):CD000486. Abstract
Fallowfield LJ et al. Intergroup exemestane study: Results of the quality of life sub-protocol. Presentation. San Antonio Breast Cancer Symposium 2004;Abstract 4.
Fallowfield L et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 2004;22(21):4261-71. Abstract
Fuqua SA, Cui Y. Estrogen and progesterone receptor isoforms: Clinical significance in breast cancer. Breast Cancer Res Treat 2004;87(Suppl 1):3-10. Abstract
Gnant M et al. Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen — Bone density subprotocol results of a randomized multicenter trial (ABCSG-12). San Antonio Breast Cancer Symposium 2004;Abstract 6.
Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract
Goss PE. Changing clinical practice: Extending the benefits of adjuvant endocrine therapy in breast cancer. Semin Oncol 2004;31(6 Suppl 12):15-22. Abstract
Grana G. Shifting paradigms in hormonal therapy for breast cancer. Cancer Biol Ther 2004;3(9):797-805. Abstract
Harvey HA. Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy. Semin Oncol 2004;31(6 Suppl 12):23-30. Abstract
Henderson IC. Aromatase inhibitors in the management of early breast cancer: Optimizing the clinical benefit. Semin Oncol 2004;31(6 Suppl 12):31-4. Abstract
Howell A et al. ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) completed treatment analysis: Anastrozole demonstrates superior efficacy and tolerability compared with tamoxifen. San Antonio Breast Cancer Symposium 2004;Abstract 1.
Howell A, Dowsett M. Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens. Breast Cancer Res 2004;6(6):269-74. Abstract
Howell A et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract
Jakesz R et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. San Antonio Breast Cancer Symposium 2004;Abstract 2.
Jones KL, Buzdar AU. A review of adjuvant hormonal therapy in breast cancer. Endocr Relat Cancer 2004;11(3):391-406. Abstract
Lipton A. Toward new horizons: The future of bisphosphonate therapy. Oncologist 2004;9(Suppl 4):38-47. Abstract
Lower EE et al. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 2005;90(1):65-70. Abstract
Rosen LS. New generation of bisphosphonates: Broad clinical utility in breast and prostate cancer. Oncology (Huntingt) 2004;18(5 Suppl 3):26-32. Abstract
Tobias JS. Recent advances in endocrine therapy for postmenopausal women with early breast cancer: Implications for treatment and prevention. Ann Oncol 2004;15(12):1738-47. Abstract
|
